ASCO GU 2023
ASCO GU 2023 Prostate Cancer
- ASCO GU 2023: Identifying Prostate Cancer Patient Subgroups Based on Their Preferences for Key Attributes of Androgen Deprivation Therapies
- ASCO GU 2023: Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer
- ASCO GU 2023: Radium-223 for mCRPC, a Real-World Experience Study from 7 Galician Medical Centers
- ASCO GU 2023: 18F-DCFPyL PET in First Biochemical Recurrence and Initial Staging: Concordance with Conventional Imaging
- ASCO GU 2023: Patterns of Failure After Radiotherapy in Patients with Prostate Cancer Re-Staged with 18F-DCFPyL PSMA-PET: A Regional Cohort Analysis
ASCO GU 2023 Bladder Cancer
- ASCO GU 2023: Sequencing Systemic Therapies and Looking to the Horizon for Metastatic Urothelial Carcinoma
- ASCO GU 2023: Radiation Therapy in Oligometastatic and Local Recurrence Urothelial Carcinoma: The What, Why, and How
- ASCO GU 2023: Biomarkers of Response to Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma: Analysis of the UNITE Study
- ASCO GU 2023: Next-Generation Therapies in Nonmuscle-Invasive Bladder Cancer
- ASCO GU 2023: Optimizing Survival for Patients With Muscle-Invasive Bladder Cancer
ASCO GU 2023 Kidney Cancer
- ASCO GU 2023: The Ever-Changing Pathologic Classification of Renal Cell Carcinoma
- ASCO GU 2023: Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate in Metastatic Renal Cell Carcinoma.
- ASCO GU 2023: Nivolumab plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced RCC: 3-Year Follow-up from the Phase 3 CheckMate 9ER Trial
- ASCO GU 2023: ZIRCON: Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma
- ASCO GU 2023: Evaluation of Deep Learning Techniques in RNA Sequencing Data for the Prediction of Response to Immune Checkpoint Inhibitors in Patients with Metastatic Renal Cell Cancer (mRCC)
ASCO GU 2023 Penile, Urethral, Testicular, and Adrenal Cancers
- ASCO GU 2023: Safety and Efficacy of Immune Checkpoint Inhibitors in Advanced Penile Squamous Cell Carcinoma: An International Study from the Global Society of Rare Genitourinary Tumors
- ASCO GU 2023: Interim Analysis of the Prospective COTRIMS (Cologne Trial of Retroperitoneal Lymphadenectomy in Metastatic Seminoma) Trial
- ASCO GU 2023: Impact of Chemotherapy on Anxiety, Depression, and Suicidality Amongst Testicular Cancer Survivors
- ASCO GU 2023: European Association of Urology Testicular Cancer Guidelines Panel: A New Prognostic Factor Risk Group Classification for Patients with Clinical Stage 1 Seminoma in Active Surveillance
ASCO GU 2023 Upper Tract Urothelial Carcinoma
- ASCO GU 2023: Radical Nephroureterectomy Followed by Adjuvant Chemotherapy Versus Observation in Early-Stage Upper Urinary Tract Cancers with Variant Histology
- ASCO GU 2023: Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Patients with Clinically Node-Positive Upper Tract Urothelial Cancer (UTUC) Who Underwent Radical Nephroureterectomy
- ASCO GU 2023: Neoadjuvant Nivolumab + Ipilimumab in Cisplatin-Ineligible Patients with Upper Tract Urothelial Cancer
- ASCO GU 2023: A SEER-Medicare Based Quality Score for Patients with Synchronous and Metachronous Metastatic Upper Tract Urothelial Carcinoma and Its Association with Cost of Care and Survival
- ASCO GU 2023: Oncologic Outcomes in Patients with Residual Invasive Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy
ASCO GU 2023 Press Releases
- Clinical Data Presented at ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC
- Cabometyx® in Combination with Nivolumab Shows Durable Survival Benefits at over Three-Years’ Follow-up in First-Line Advanced Renal Cell Carcinoma
- Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
- Diet Higher in Plants Associated With Lower Risk of Prostate Cancer Progression and Recurrence
- ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)